Key clinical point: TAVR is now a reasonable option for patients with bicuspid AS who are at intermediate or high surgical risk.
Major finding: The 1-year all-cause mortality rates were 10.8% in patients who underwent TAVR for bicuspid AS and similar at 12.1% following TAVR for tricuspid AS.
Study details: This was a study of outcomes in 2,691 patients in the STS/ACC Transcatheter Valve Therapy Registry who underwent TAVR for bicuspid AS and an equal number of propensity-matched patients who had TAVR for tricuspid AS.
Disclosures: The study was supported by Edwards Lifesciences. The presenter reported receiving research grants from and serving as a consultant to that company and several other medical device makers.
Makkar RR. ACC 19, 404-15. Late breaking clinical trials